Cargando…

Therapy of membranous nephropathy: quo vadis?

Detalles Bibliográficos
Autor principal:	Glassock, Richard J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Pro/Con Debate
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468741/ https://www.ncbi.nlm.nih.gov/pubmed/37664562 http://dx.doi.org/10.1093/ckj/sfad074

Ejemplares similares

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
por: Zand, Ladan, et al.
Publicado: (2023)

Is too much salt harmful? Yes
por: Agócs, Róbert, et al.
Publicado: (2019)

When comparing the safety of drugs, don't forget the exposure dimension
por: Zoccali, Carmine
Publicado: (2023)

Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…
por: Carrero, Juan Jesus, et al.
Publicado: (2023)

Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!
por: Rossignol, Patrick, et al.
Publicado: (2023)

Dietary sodium and cardiovascular and renal disease risk factors: dark horse or phantom entry?
por: McCarron, David A.
Publicado: (2008)

Pro con debates in clinical medicine infection prevention and control in cystic fibrosis: One size fits all? The argument in favour
por: Haggie, S., et al.
Publicado: (2020)

Congenital nephrotic syndrome: is early aggressive treatment needed? Yes
por: Hölttä, Tuula, et al.
Publicado: (2020)

The term CAKUT has outlived its usefulness: the case for the prosecution
por: Woolf, Adrian S.
Publicado: (2022)

The term CAKUT has outlived its usefulness: the case for the defense
por: Knoers, Nine V. A. M.
Publicado: (2022)

Con: Venoarterial ECMO Should Not Be Considered in Patients With COVID-19
por: McLean, Duncan J., et al.
Publicado: (2021)

Pro: Integrated Five-Year Anesthesiology Residency Should Be Implemented Widely
por: Kovar, Alan J., et al.
Publicado: (2023)

Con: Integrated 5-Year Anesthesiology Residency Should Be Implemented Widely
por: Phillips, Thomas
Publicado: (2023)

Interacting with the Pharmaceutical Industry
por: Hayden, Stephen R.
Publicado: (2003)

Should Academic Emergency Departments Collaborate in Pharmaceutical Industry-Sponsored Research?: The Dangers of Industry-Funded Research in Emergency Medicine
por: Stone, Susan, et al.
Publicado: (2003)

Advantages of a Three-year Residency
por: Langdorf, Mark, et al.
Publicado: (2004)

Why the US Government Should Not Adopt a Universal Health Coverage Program
por: Montauk, Lance
Publicado: (2004)

Con: Should Evidence-Based Medicine Be Used More in Clinical Practice?
por: Maxim, Preston
Publicado: (2006)

Rebuttal of Con
por: Fee, Chris
Publicado: (2006)

Rebuttal of Pro
por: Maxim, Preston
Publicado: (2006)

Pro: Should Evidence-Based Medicine Be Used More in Clinical Practice?
por: Fee, Chris
Publicado: (2006)

Pro: Venoarterial ECMO Should Be Considered in Patients With COVID-19
por: Bhatia, Meena, et al.
Publicado: (2021)

Rheumatologie – quo vadis? Gesundheitssystem – quo vadis?
por: Puchner, Rudolf
Publicado: (2023)

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant?: Pro: Provide pre-emptive treatment to asymptomatic carriers
por: de Boer, Rudolf A.
Publicado: (2023)

Quo Vadis?
por: Happel, T. J.
Publicado: (1899)

“Quo Vadis?”
por: Bereen, J. F.
Publicado: (1964)

Quo Vadis?
Publicado: (1902)

Quo vadis?
por: Sienkiewicz, Henryk, 1846-1916
Publicado: (1943)

Quo vadis? /
por: Sienkiewicz, Henryk, 1846-1916

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Bergbaukunde, quo vadis?
por: Tost, Michael, et al.
Publicado: (2023)

HDL – Quo vadis
por: von Eckardstein, Arnold, et al.
Publicado: (2023)

Aromaticity: Quo Vadis
por: Merino, Gabriel, et al.
Publicado: (2023)

Quo vadis, Kras?
por: Schneider, Günter, et al.
Publicado: (2013)

AERD: Quo Vadis?
por: Bosso, John V.
Publicado: (2020)

Remdesivir: Quo vadis?()
por: De Clercq, Erik
Publicado: (2021)

Quo Vadis Influenza?
por: Neumann, Gabriele, et al.
Publicado: (2021)

Quo vadis Impfpflicht?
por: Hötzenecker, Wolfram, et al.
Publicado: (2022)

The Physiology of Reproduction – Quo vadis?
por: Ivell, Richard, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ro4olcaa8bf2jjjm1tm4ltlcpa